In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please amend claims 1-8, cancel claim 9, and add new claims 12-17 as follows.

1. (currently amended) A compound in accord with structural diagram I:



I

wherein:

R^1 at each occurrence is independently selected from CN, CF_3, OCF_3, $OCHF_2$, halogen, C_{2-4}alkenyl, C_{2-4}alkynyl, R^a, R^b, SR^a, NR^aR^b, $CH_2NR^aR^b$, OR^a or CH_2OR^a, where R^a and R^b are independently at each occurrence hydrogen, C_{1-6}alkyl, $C(O)R^c$, $C(O)NHR^c$ or CO_2R^c, where R^c at each occurrence is C_{1-6}alkyl; or, R^a and R^b together are $(CH_2)_jG(CH_2)_k$ or $G(CH_2)_jG$, where G is oxygen or sulfur, j is 1, 2, 3 or 4, and k is 0, 1 or 2;

m is 1, 2 or 3 where at least one R^1 moiety is other than hydrogen;

R^2 and R^3 are independently hydrogen, C_{1-6}alkyl or C_{1-6}alkyl substituted with C_{1-4}alkoxy;

R^4 at each occurrence is independently selected from hydrogen, CN, CF_3, OCF_3, $OCHF_2$, halogen, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, SR^a, NR^aR^b, $CH_2NR^aR^b$, OR^a or CH_2OR^a, where R^a and R^b are independently at each occurrence hydrogen, C_{1-6}alkyl, $C(O)R^c$, $C(O)NHR^c$ or CO_2R^c, where R^c at each occurrence is C_{1-6}alkyl; or, R^a and R^b together are $(CH_2)_jG(CH_2)_k$ or $G(CH_2)_jG$; and

n is 0, 1, 2 or 3;

~~in vivo hydrolysable precursors thereof, and~~ or a pharmaceutically-acceptable ~~salts~~ salt thereof.

2. (currently amended) A compound according to Claim 1, wherein:

R^1 independently at each occurrence is CN, C_{1-6}alkyl or OR^c and m is 1, 2 or 3;

R^2 and R^3 are independently hydrogen or C_{1-6}alkyl, and

R^4 independently at each occurrence is halogen where n is 1 or 2;

~~in vivo hydrolysable precursors thereof, and~~ or a pharmaceutically-acceptable ~~salts~~ salt thereof.

3. (currently amended) A compound according to Claim 1, wherein:

R^1 independently at each occurrence is CN, ethyl or methoxy and m is 1, 2 or 3;

R^2 and R^3 are independently hydrogen or methyl, and

R^4 independently at each occurrence is halogen where n is 1 or 2;

R^4 independently at each occurrence is halogen where n is 1 or 2;

~~in vivo hydrolysable precursors thereof, and~~ or a pharmaceutically-acceptable ~~salts~~ salt thereof.

4. (currently amended) A compound according to Claim 1, according to structural diagram II



II

wherein Ar is selected from phenyl, 3,4-dichlorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3,4-methylenendioxyphenyl, 4-difluoromethoxyphenyl or 4-trifluoromethoxyphenyl;

R^1 is selected from H, methyl, ethyl or methoxy where m is 1 or 2, and

R^2 and R^3 are independently ~~is~~ selected from H or methyl, and

~~in vivo hydrolysable precursors thereof, and~~ or a pharmaceutically-acceptable ~~salts~~ salt thereof.

5. (currently amended) A pharmaceutically-acceptable ~~salts~~ salt of a compound according to Claim 1 made with an inorganic or organic acid which affords a physiologically-acceptable anion.

6. (currently amended) A pharmaceutically-acceptable ~~salts~~ salt of a compound according to Claim 5, wherein said inorganic and organic acid is selected from hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, sulfamic, para-toluenesulfonic, acetic, citric, lactic, tartaric, malonic, fumaric, ethanesulfonic, benzenesulfonic, cyclohexylsulfamic, salicyclic and quinic acids.

7. (currently amended) A pharmaceutical composition comprising a compound accoring to Claim 1, ~~an in vivo hydrolysable precursor~~ or a pharmaceutically-acceptable salt thereof and a pharmaceutically-acceptable carrier.

8. (currently amended) A method of treating a disease condition wherein antagonism of NK_1 receptors in combination with SRI activity is beneficial which method comprises administering to a warm-blooded animal an effective amount of a compound according to Claim 1 ~~or an in vivo hydrolysable precursor~~ or a pharmaceutically acceptable salt thereof.

9. (canceled).

10. (original) A method for treating a disorder or condition selected from hypertension, depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, post partum depression, generalized anxiety disorder, agoraphobia, social phobia, simple phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, anorexia nervosa, bulimia nervosa, obesity, addictions to alcohol, cocaine, heroin, phenobarbital, nicotine or benzodiazepines; cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, dementia, amnestic disorders, age-related cognitive decline, dementia in Parkinson's disease, neuroleptic-induced parkinsonism, tardive

dyskinesias, hyperprolactinaemia, vasospasm, cerebral vasculature vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder, chronic paroxysmal hemicrania and headache associated with vascular disorders in a mammal, comprising administering an effective amount of a compound according to Claim 1 or a pharmaceutically-acceptable salt thereof effective in treating such disorder or condition and a pharmaceutically-acceptable carrier.

11. (canceled).

12. (new) A compound in accord with structural diagram I:



I

wherein:

R^1 at each occurrence is independently selected from hydrogen, CN, CF_3, OCF_3, $OCHF_2$, halogen, C_{1-6}alkoxy, C_{2-4}alkenyl, or C_{2-4}alkynyl;

m is 1, 2 or 3 where at least one R^1 moiety is other than hydrogen;

R^2 and R^3 are independently hydrogen or C_{1-6}alkyl;

R^4 at each occurrence is independently selected from hydrogen, CF_3, OCF_3, $OCHF_2$, halogen, C_{1-4}alkyl, C_{2-4}alkenyl, or C_{2-4}alkynyl, where R^a and R^b are independently at each occurrence hydrogen, C_{1-6}alkyl, $C(O)NHR^c$ or CO_2R^c, where R^c at each occurrence is C_{1-6}alkyl; and

n is 0, 1, 2 or 3;

or a pharmaceutically-acceptable salt thereof.

13. (new) A compound according to Claim 12, wherein:

R^1 at each occurrence is independently selected from hydrogen, CN, C_{1-6}alkyl, C_{1-6}alkoxy, halogen, or CF_3;

m is 1, 2 or 3 where at least one R^1 moiety is other than hydrogen;

R^2 and R^3 are independently hydrogen, C_{1-6}alkyl, or C_{1-6}alkoxy;

R^4 at each occurrence is independently selected from hydrogen, CF_3, OCF_3, $OCHF_2$, halogen, C_{1-4}alkyl, C_{2-4}alkenyl, and C_{2-4}alkynyl; and

n is 0, 1, 2 or 3;

or a pharmaceutically-acceptable salt thereof.

14. (new) A compound according to Claim 13, wherein:

R^1 at each occurrence is independently selected from hydrogen, CN, C_{1-6}alkyl, methoxy, or halogen;

m is 1, 2 or 3;

R^2 and R^3 are independently hydrogen, methyl, ethyl, or ethoxy;

R^4 at each occurrence is hydrogen or halogen; and

n is 1 or 2;

or a pharmaceutically-acceptable salt thereof.

15. (new) A compound according to Claim 1, according to structural diagram II



II

wherein Ar is selected from phenyl, 3,4-dichlorophenyl, 3-fluorophenyl, 4-fluorophenyl, or 3,4-difluorophenyl;

R^1 is selected from hydrogen or methoxy, where m is 1 or 2, and

R^2 and R^3 are independently selected from hydrogen or methyl;

or a pharmaceutically-acceptable salt thereof.

16. (new) A method for treating a disorder or condition selected from, depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, post partum depression, comprising administering an effective amount of a compound according to Claim 1 or a pharmaceutically-acceptable salt thereof effective in treating such disorder or condition and a pharmaceutically-acceptable carrier.

17. (new) A method for treating a disorder or condition selected from generalized anxiety disorder, agoraphobia, social phobia, simple phobias, posttraumatic stress syndrome, avoidant personality disorder, obsessive-compulsive disorder, panic disorder, comprising administering an effective amount of a compound according to Claim 1 or a pharmaceutically-acceptable salt thereof effective in treating such disorder or condition and a pharmaceutically-acceptable carrier.